Ipamorelin vs GHRP-2 — Comparing Selective and First-Generation GHRPs

Ipamorelin and GHRP-2 share the same proximal target — the ghrelin receptor, formally GHSR-1a — and both were developed as synthetic tools to stimulate pulsatile growth hormone release from pituitary somatotrophs without administering exogenous GH directly. At that level of description they are near-equivalents. Look more closely, however, and the two peptides represent different generations of GHRP design philosophy: GHRP-2 is a first-generation hexapeptide that produces a powerful but non-selective receptor activation event, while ipamorelin is a purpose-engineered pentapeptide that achieves comparable GH stimulation with a markedly cleaner hormonal fingerprint. Understanding where those differences originate — and what they mean for research design — is the purpose of this comparison.

Research context only. Neither compound is approved for human use in the UK, EU, or US. Nothing on this page constitutes medical advice. Dosing figures and protocol details reflect published preclinical and clinical-trial literature only.

Origins and development history

GHRP-2 (pralmorelin; also known as KP-102) belongs to the first wave of synthetic growth hormone-releasing peptides identified by Cyril Bowers and colleagues in the 1980s and early 1990s. Working from enkephalin analogues, Bowers' group at Tulane systematically modified peptide structures to find those capable of stimulating GH secretion independently of native GHRH. GHRP-2 — a six-amino-acid sequence (D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH2) — emerged as one of the most potent members of this series [PMID:7678130]. It became a standard tool in endocrinology research and diagnostic testing of the GH axis through the 1990s and 2000s; its reliable, reproducible GH spike made it useful for pituitary reserve assays.

Ipamorelin arrived roughly a decade later from a different design philosophy. Raun, Hansen, Johansen and colleagues at Novo Nordisk were not merely trying to find another GH releaser — they were specifically hunting for one that released GH without the cortisol, ACTH, and prolactin co-elevations that plagued first-generation GHRPs including GHRP-2. Their 1998 paper in the European Journal of Endocrinology described the pentapeptide NNC 26-0161, later named ipamorelin, as the first truly selective growth hormone secretagogue [PMID:9849822]. That selectivity — rather than raw GH-releasing potency — was the explicit design objective, and it is the defining feature that separates ipamorelin from its predecessor.

Shared receptor, divergent selectivity

Both peptides bind GHSR-1a, and both activate the Gαq/11 intracellular cascade that raises intracellular calcium in pituitary somatotrophs, triggering exocytosis of GH-containing secretory granules. At this receptor-level description the pharmacology is similar. The critical divergence lies in what else each compound activates beyond the primary GH-secretory pathway.

GHRP-2 drives a robust acute GH pulse, but the same receptor activation events at hypothalamic and adrenal sites produce measurable co-elevation of cortisol, ACTH, and in some studies prolactin. Pihoker and colleagues documented significant cortisol and ACTH rises in children following GHRP-2 administration, confirming that the HPA-axis activation is pharmacologically real rather than an artefact of assay sensitivity [PMID:7678130]. The magnitude of these co-elevations is dose-dependent and does not disappear at lower doses within the GH-stimulating range — meaning researchers using GHRP-2 must account for HPA-axis perturbation when interpreting any outcome measure that could be influenced by acute cortisol elevation, including immune markers, glucose metabolism, and subjective state reports.

Ipamorelin produces GH pulses of comparable magnitude to GHRP-2 at research-relevant doses, but the cortisol and ACTH co-elevations are negligible across a wide dose range. Johansen, Raun, Hansen and colleagues explicitly demonstrated this in comparative assays in both rat and porcine models: at equimolar doses that produced matched GH release, ipamorelin drove no significant cortisol or prolactin elevation while GHRP-2 drove measurable increases in both [PMID:10373343]. The selectivity was maintained even when ipamorelin was administered at doses substantially above the effective GH-releasing dose — a practical advantage, because many first-generation GHRPs that appear selective at low doses lose that selectivity as concentrations rise.

The mechanistic basis for this selectivity difference is not fully resolved, but structural analyses suggest that the D-2-naphthylalanine residue at position three of ipamorelin's pentapeptide sequence confers receptor binding geometry that engages the somatotroph pathway efficiently while failing to activate the corticotroph-linked conformational states that GHRP-2's structure induces.

GH pulse magnitude and kinetics

On raw GH-releasing potency, GHRP-2 has a genuine advantage. Head-to-head comparisons in both rat pituitary cell assays and human GH-axis studies consistently show that GHRP-2 drives a higher acute GH peak than ipamorelin at comparable molar doses. Sigalos and Pastuszak's 2018 review of GH secretagogue pharmacology confirmed GHRP-2 as among the most potent GHRPs in terms of absolute GH pulse amplitude [PMID:29190343].

For many research protocols, however, peak amplitude is less important than the shape and hormonal context of the pulse. A large GH spike accompanied by a cortisol elevation confounds interpretation in any study where cortisol-sensitive outcomes are measured — and cortisol influences protein turnover, fat mobilisation, immune function, sleep architecture, and numerous other endpoints that investigators may be tracking. Ipamorelin's lower absolute GH peak, delivered without the cortisol co-signal, produces a cleaner experimental condition in those contexts.

The kinetic profiles of the two compounds differ substantially. GHRP-2 has a plasma half-life of approximately thirty minutes, meaning a single injection produces a GH pulse that rises and falls relatively quickly. Ipamorelin's half-life is approximately two hours, producing a longer-lasting receptor occupancy and a somewhat more sustained — though still pulsatile — GH release profile. Gobburu and colleagues modelled ipamorelin's pharmacokinetics and pharmacodynamics in human volunteers and found GH peak concentrations reached maxima at roughly fifteen to thirty minutes post-injection, returning toward baseline within approximately three hours — a kinetic shape that is compatible with preserving the inter-pulse troughs that maintain pituitary somatotroph sensitivity [PMID:10592337].

Research dosing comparison

In published preclinical and early human studies, the dosing strategies for the two compounds reflect their kinetic profiles.

GHRP-2 is typically administered at 100 to 300 µg per injection by subcutaneous or intravenous route. In diagnostic applications — where a single-point pituitary stimulation test is the objective — a single one-hundred-microgram bolus has been used as a standardised stimulus to assess GH reserve. In research protocols targeting chronic GH-axis activation, two to three daily injections are more common, reflecting the short half-life and the need to produce repeated GH pulses across the day.

Ipamorelin is similarly dosed at 200 to 300 µg per injection, subcutaneously, with three daily administrations representing the most common research cadence. The longer half-life means the inter-injection interval can be somewhat more flexible, but three daily doses remain the standard approach when approximating physiological GH pulsatility is the goal. When co-administered with CJC-1295 no-DAC — the most extensively documented ipamorelin pairing — the two compounds are typically injected together at the same site, leveraging the synergistic GHRH-receptor and GHSR-1a co-activation that produces GH pulses substantially larger than either compound alone.

CJC-1295 pairing: historical GHRP-2 vs current ipamorelin preference

One of the most practically relevant differences between these two GHRPs is their relationship to CJC-1295 (no-DAC) pairing in research protocols.

GHRP-2 was historically paired with GHRH analogues including CJC-1295 no-DAC, based on the same mechanistic rationale that applies to any GHRP: GHRH-receptor agonism and GHSR-1a agonism operate through non-competing intracellular pathways in the same somatotroph cell, and simultaneous activation of both pathways produces synergistic GH release that exceeds either agent alone. During the period when GHRP-2 was the most widely studied GHRP in combination research, these pairings were productive and well-characterised.

The shift toward ipamorelin as the preferred GHRP partner for GHRH analogues occurred gradually as the selectivity data became better appreciated. Researchers who needed clean GH pulses without cortisol confounding migrated toward ipamorelin, and the combination of CJC-1295 no-DAC plus ipamorelin has effectively become the reference GHRP-GHRH pairing in current GH-axis research. The synergistic amplitude advantage that justified GHRH-GHRP combination dosing applies equally to both compounds; the selectivity difference is the reason ipamorelin is now preferred as the GHRP element.

For investigators working with legacy protocols or datasets based on GHRP-2 and CJC-1295, the combination remains mechanistically valid. The cortisol co-elevation should be treated as a confounding variable and measured alongside GH and IGF-1 endpoints rather than ignored.

When GHRP-2 retains research utility

Despite ipamorelin's advantages in selectivity, GHRP-2 is not obsolete as a research compound.

Investigators specifically studying first-generation GHRP pharmacology — including receptor kinetics, corticotroph pathway crosstalk, or the mechanism of HPA co-activation by GHSR-1a agonists — require GHRP-2 as the reference compound. Its well-characterised cortisol response makes it a useful positive control in assays designed to measure HPA-axis sensitivity or to test whether a novel intervention suppresses cortisol co-elevation from GHSR-1a agonism.

GHRP-2's stronger acute GH spike is also an advantage in contexts where maximum GH pulse amplitude is itself the variable of interest — for instance, in assays benchmarking new compounds against a maximal first-generation stimulant, or in short-duration studies where peak amplitude is the primary pharmacodynamic readout.

Finally, GHRP-2 has a longer published track record as a GH-axis diagnostic stimulus. Its use in formal pituitary reserve testing protocols — where a standardised, maximal GH-releasing challenge is needed to diagnose GH deficiency — is better characterised across age groups and clinical populations than ipamorelin's use in the same context.

For a full monograph on GHRP-2 including mechanism detail, historical trial data, and dosing reference, see the compound profile at PeptideAuthority, where GHRP-2's research history is comprehensively documented.

Regulatory standing

Both compounds are unapproved research chemicals in the United Kingdom, European Union, and United States.

Neither ipamorelin nor GHRP-2 holds a Marketing Authorisation from the MHRA or EMA, and neither appears on the British National Formulary. Neither is scheduled under the Misuse of Drugs Act 1971. Supply for human administration constitutes supply of an unlicensed medicinal product under the Human Medicines Regulations 2012 and requires MHRA authorisation not currently available for either compound. Both are legally held in UK institutional settings only as research chemicals for in vitro or non-human laboratory research purposes.

GHRP-2 (pralmorelin) has been investigated in formal clinical trials — including licensed GH stimulation test applications in Japan — but does not hold full marketing authorisation in European or North American jurisdictions for any therapeutic indication as of May 2026.

Choosing between Ipamorelin and GHRP-2

The selection decision rests primarily on whether hormonal selectivity or acute GH amplitude is the dominant design priority.

Choose ipamorelin when the research protocol requires clean, selective GH pulses without HPA-axis co-activation; when outcomes include any measure that could be confounded by acute cortisol elevation; when the compound will be paired with a GHRH analogue such as CJC-1295 no-DAC in a synergistic pulsatile protocol; or when multi-week dosing with a broader safety margin for HPA impact is preferred. Ipamorelin's two-hour half-life and three-daily injection schedule are also operationally straightforward. See the Ipamorelin monograph for the full mechanistic and pharmacokinetic reference.

Choose GHRP-2 when the research specifically targets first-generation GHRP pharmacology or HPA co-activation mechanisms; when maximum acute GH pulse amplitude is the primary endpoint; when historical comparability with legacy GHRP-2 datasets is required; or when a standardised maximal pituitary stimulation challenge analogous to established diagnostic protocols is needed.

Related stacks

Both compounds fit mechanistically into GHRH-GHRP combination protocols, but current research stacks on this site use ipamorelin as the GHRP element based on its selectivity profile.

The CJC-1295 + Ipamorelin + Tesamorelin GH Stack combines ipamorelin with CJC-1295 no-DAC for synergistic pulsatile GH release and adds tesamorelin's sustained GHRHR activation to the nocturnal GH secretory window — a three-way protocol addressing pulse architecture, amplitude, and VAT research endpoints simultaneously.

The Ipamorelin + CJC-1295 + BPC-157 Recomp Stack pairs the core GHRH-GHRP combination with BPC-157, a systemically active pentadecapeptide with documented connective-tissue and gut-motility effects in rodent models, extending the protocol from pure GH-axis stimulation into peripheral tissue-repair research.

For the complete mechanistic profile of ipamorelin — including its discovery history, receptor pharmacology, safety signal, reconstitution guidance, and UK regulatory standing — see the Ipamorelin peptide monograph.

Verdict — research-question matching

Ipamorelin is the preferred GHRP in current research protocols, principally because its selectivity profile eliminates the cortisol and prolactin co-elevation that complicates interpretation of data generated with GHRP-2. For researchers whose primary endpoint is clean, pulsatile GH release without HPA-axis interference, ipamorelin is the cleaner tool — see the full [Ipamorelin monograph](/peptides/ipamorelin) for mechanism and dosing detail, and the [CJC-1295 + Ipamorelin + Tesamorelin GH Stack](/stacks/cjc-1295-ipamorelin-tesamorelin-gh-stack) and [Ipamorelin + CJC-1295 + BPC-157 Recomp Stack](/stacks/ipamorelin-cjc-1295-bpc-157-recomp-stack) for protocol context. GHRP-2 retains historical research value and still produces a stronger acute GH spike in head-to-head assays; for investigators working with historical comparator data or specifically examining first-generation GHRP pharmacology, GHRP-2 remains a legitimate reference compound.